Aflibercept 2mg biosimilars for use in ophthalmology are expected in December 2025 for NHS use. We offer general information and implementation advice.
The availability of medicines used to treat Attention Deficit Hyperactivity Disorder (ADHD) varies currently. Supply content is maintained regularly by DHSC.
A community pharmacist, GP, and primary care team share how blood pressure management has strengthened Access and Recovery services and improved patient care.
Latest information on supply issues, actions to take, alternatives to use, and expected resolution dates. Content provided by DHSC and MVA team, NHS England.
Delegation of any PGD function is not permitted. However there are specific tasks that individuals other than the professional working under a PGD can fulfil.
Understanding when PGDs are a suitable mechanism for the supply and/or administration of medicines ensures an appropriate legal framework for service provision.
Understanding when PGDs are an unsuitable mechanism for the supply and/or administration of medicines ensures an alternative legal framework is applied.
Understanding where PGDs can and cannot be used for the supply and/or administration of P and GSL medicines helps ensure correct legal mechanisms in practice.
If you're a healthcare professional who needs further advice, get in touch with us. You can contact us through our single email or telephone number below. Please don't share patient identifiable data with us by email.
Practical guidance to ensure opportunities to learn from local intelligence, including patient harm are translated into shared local and national learning
Healthcare professionals delivering the medication safety agenda in their organisation require an understanding of national policy, frameworks and legislation
Effective use provides assurance that an organisation is aware of the most critical medication safety related information, and acts on this to improve safety